Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the marketing application of its chemical substance drug, Icosapent Ethyl. This approval allows the company to market the drug, which is used to reduce triglyceride levels in adults with severe hypertriglyceridemia, potentially enhancing its market position and offering new treatment options for cardiovascular conditions.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and marketing of chemical substance drugs. The company is involved in the pharmaceutical industry and aims to expand its market presence with innovative drug solutions.
Average Trading Volume: 3,206,559
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.61B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.